<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16-pathogens-08-00216">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Currier</surname>
    <given-names>J.R.</given-names>
   </name>
   <name>
    <surname>Ngauy</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>de Souza</surname>
    <given-names>M.S.</given-names>
   </name>
   <name>
    <surname>Ratto-Kim</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Cox</surname>
    <given-names>J.H.</given-names>
   </name>
   <name>
    <surname>Polonis</surname>
    <given-names>V.R.</given-names>
   </name>
   <name>
    <surname>Earl</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Moss</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Peel</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Slike</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate</article-title>
  <source>PLoS ONE</source>
  <year>2010</year>
  <volume>5</volume>
  <elocation-id>e13983</elocation-id>
  <pub-id pub-id-type="doi">10.1371/journal.pone.0013983</pub-id>
  <pub-id pub-id-type="pmid">21085591</pub-id>
 </element-citation>
</ref>
